Unknown

Dataset Information

Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer.


ABSTRACT:

Background

Evidence for the efficacy of immunotherapy in biliary tract cancer (BTC) is limited and unsatisfactory.

Methods

Chinese BTC patients receiving a PD-1 inhibitor with chemotherapy, PD-1 inhibitor monotherapy or chemotherapy alone were retrospectively analyzed. The primary outcome was overall survival (OS). The key secondary outcomes were progression-free survival (PFS) and safety. Patients previously treated with any agent targeting T cell costimulation or immune checkpoints were excluded.

Results

The study included 77 patients (a PD-1 inhibitor plus chemotherapy, n = 38; PD-1 inhibitor monotherapy, n = 20; chemotherapy alone, n = 19). The median OS was 14.9 months with a PD-1 inhibitor plus chemotherapy, significantly longer than the 4.1 months with PD-1 inh

SUBMITTER: Sun D 

PROVIDER: S-EPMC6768892 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature